Lead sponsor
Xijing Hospital
2 GLP-1 and incretin trials led. Source: ClinicalTrials.gov, as of July 1, 2026.
2
Trials led
0
Active
210
Total enrollment
3
Sites
Distinct sites across this sponsor's lead trials. A site running several of them counts once, matching the map. Total enrollment sums each trial's reported enrollment, whether planned or actual.
Portfolio
How this sponsor's trials break down
Trials by phase
Phase 4
1
Not applicable
1
Trials by status
Completed
2
Trials led
TrialKey I/E criterionPhaseStatusEnrollment
Comparison of Exenatide vs. Biphasic Insulin Aspart 30 on Glucose Variability in Type 2 DiabetesBMI 21-35Ph 4Completed150
Study for Beinaglutide Versus Glargine Therapy in Glycemic Variability of Type 2 Diabetes MellitusBMI ≤35not applicableCompleted60